Welcome to Gedeon Richter PregLem

Pioneering first-in-class medical treatments in reproductive medicine

Learn more

Developing first-in-class therapies for gynaecologic conditions with significant unmet needs

Learn more

Changing the rules of treatment, drug performance and innovations

Learn more

Preserving the integrity of womanhood

Learn more

aboutGedeon Richter PregLem SA is a Swiss-based speciality biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine. PregLem is a member of the Richter Group.

PregLem’s activities focus on developing therapies for gynaecologic conditions with significant unmet needs and that have a severe impact on the patient’s quality of life:


RD

Esmya®
(Ulipristal Acetate/PGL4001)

Completed Ph III
EMA approval as a pre-operative treatment of moderate to severe symptoms of uterine fibroids received in February 2012

PGL2001
(Steroid Sulfatase Inhibitor, STS-I)

Mild or Moderate Endometriosis: Phase IIa

PGL5001
(c-Jun-N-Terminal Kinase Inhibitor (JNK-I), Bentamapimod)

Inflammatory Endometriosis: Phase IIa / Proof of Concept (POC)
Adhesions: Phase IIa/Proof of Concept (POC)

PGL1001
(Somatostatin Antagonist, SST-ATG)

Ovarian Reserve Modulation: Pre-clinical development

press

Latest news

Submit your e-mail address to receive news updates by email

Register now

Press room

Visit now